secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medline Inc. (MDLN)
CIK:        0002046386
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0002046386-26-000022
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medline Q1 sales up 10.7% to $7.4B; net income down 25.8%, adjusted EBITDA down 10.6%
--------------------------------------------------------------------------------

- Net income $239M (-25.8% YoY); Diluted EPS $0.16; Adjusted Diluted EPS $0.33.
- Organic sales growth 10.1%; total sales $7.4B driven by new customer signings and existing customer growth.
- Adjusted EBITDA $776M (-10.6% YoY) on higher tariffs, operating expenses, and IPO-related bonus.
- Raising full-year organic sales guidance to 8.5%-9.5% (prior 8%-9%); maintaining adjusted EBITDA outlook $3.5-$3.6B.
- Free Cash Flow $316M; net cash from ops $412M, capex for distribution centers and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2046386/000204638626000022/0002046386-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2046386/000204638626000022/mdln-20260506.htm
  HTML page:      https://secwatch.observer/filing/0002046386-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer